Oliver Lenz

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Ira M. Jacobson, Gregory J. Dore, Graham R. Foster et al. · The Lancet · 2014 · 436 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Michael P. Manns, Patrick Marcellin, Fred Poordad et al. · The Lancet · 2014 · 375 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study

Michael Fried, Gregory J. Dore, Robert Flisiak et al. · Hepatology · 2013 · 271 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial

Xavier Forns, Eric Lawitz, Stefan Zeuzem et al. · Gastroenterology · 2014 · 256 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial

Stefan Zeuzem, Thomas Berg, Edward Gane et al. · Gastroenterology · 2013 · 235 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12